Valuation : Crinetics Pharmaceuticals, Inc.

Market Cap 9B 7.77B 7.28B 6.65B 12.51B 858B 12.57B 86.31B 33.7B 434B 33.78B 33.05B 1,440B P/E 2026 *
-18.2x
P/E 2027 * -20.7x
Enterprise Value 7.99B 6.9B 6.47B 5.91B 11.11B 762B 11.17B 76.67B 29.93B 386B 30.01B 29.35B 1,279B EV / Sales 2026 *
104x
EV / Sales 2027 * 46.3x
Free-Float
98.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Crinetics Pharmaceuticals, Inc.

1 day-0.01%
1 week+0.18%
Current month+1.58%
1 month+1.17%
3 months+135.60%
6 months+106.42%
Current year+82.26%
1 week 84.71
Extreme 84.71
84.88
1 month 83.47
Extreme 83.47
84.88
Current year 32.3
Extreme 32.3
84.88
1 year 31
Extreme 31
84.88
3 years 15.76
Extreme 15.76
84.88
5 years 15.23
Extreme 15.23
84.88
10 years 10.63
Extreme 10.63
84.88
Manager TitleAgeSince
Chief Executive Officer 64 2008-11-30
Chief Tech/Sci/R&D Officer 60 2021-09-30
Director of Finance/CFO 51 2025-02-27
Director TitleAgeSince
Chairman 78 2015-09-30
Director/Board Member 64 2008-10-31
Director/Board Member 61 2018-01-31
Date Insider Type Main position Quantity % Market Cap.
8/20/26 Free

Chief Financial Officer

471 0.0004%
8/7/26 Fiscal year

Founder

39,856 0.0378%
7/2/26 Sell

Director

-3,000 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
-0.01%+0.18%+176.80%+398.18% 9B
-1.59%-3.35%+64.49%+98.69% 69.54B
-1.34%-0.75%+48.56%+90.63% 64.97B
-8.37%-12.43%+0.14%-15.42% 25.64B
-2.35%-5.75%-12.17%+448.29% 25.89B
+0.30%-0.69%+63.18%+11.93% 26.51B
-0.96%+10.36%+278.86%+438.78% 20.22B
-0.51%+0.23%+33.71%-18.02% 19.98B
-1.91%-4.37%+13.33%+531.29% 15.69B
-1.47%+0.68%+43.67%+145.49% 13.49B
Average -1.82%-1.72%+71.06%+212.98% 29.09B
Weighted average by Cap. -1.87%-1.45%+60.85%+160.41%

Financials

2026 *2027 *
Net sales 76.86M 66.36M 62.2M 56.79M 107M 7.33B 107M 737M 288M 3.71B 289M 282M 12.3B 180M 156M 146M 133M 251M 17.21B 252M 1.73B 676M 8.7B 677M 663M 28.88B
Net income -507M -438M -411M -375M -705M -48.4B -709M -4.87B -1.9B -24.47B -1.91B -1.86B -81.21B -463M -400M -375M -342M -644M -44.2B -647M -4.45B -1.74B -22.35B -1.74B -1.7B -74.17B
Net Debt -1.01B -868M -814M -743M -1.4B -95.9B -1.4B -9.64B -3.77B -48.49B -3.77B -3.69B -161B -647M -559M -524M -478M -899M -61.71B -904M -6.21B -2.42B -31.2B -2.43B -2.38B -104B
Logo Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Employees
594
Date Price Change Volume
26-08-28 US$84.84 -0.01% 1,127,886
26-08-27 US$84.85 +0.01% 1,058,995
26-08-26 US$84.84 -0.02% 479,524
26-08-25 US$84.86 +0.09% 1,241,641
26-08-24 US$84.78 +0.11% 908,510
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
84.84USD
Average target price
85.50USD
Spread / Average Target
+0.78%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRNX Stock